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The impact of pre-treatment intervals on the antipseudomonal efficacy of genta-
micin, ticarcillin and ceftazidime was studied in an experimental thigh infection
model in normal and granulocytopenic mice. Human-equivalent doses were used for
simulating human pharmacokinetic profiles of the two study 0-lactam drugs. A
lethal inoculum of a virulent strain of Pseudomonas aeruginosa was injected into the
thigh muscle. Treatment was started at various post-infection intervals.
Antimicrobial efficacy was assessed by determinations of surviving organisms at the
site of infection, and plasma drug concentrations were determined in the same mice.
The age of infection had a substantial impact on antipseudomonal efficacy of the
three study drugs even though high, brief supra-MIC concentrations of gentamicin
and persistent supra-MIC concentrations of the /Mactam drugs were obtained. A
pre-treatment interval of six or more hours abolished the bactericidal effect of all
three study drugs despite accumulation of the drugs to multiple-MBC plasma
concentrations. We believe that the impact of pre-treatment intervals on anti-
microbial efficacy is of paramount importance for the interpretation of antimicrobial
activity studies in experimental models of infection, although the mechanisms
remain to be elucidated.
Introduction
Many different factors are known to affect antimicrobial efficacy in vivo. Some of these
factors, such as the infecting microorganisms, the site of infection and the intrinsic
activity of an antimicrobial agent and its pharmacokinetic behaviour, have been well
recognized and investigated in experimental models of infection (Drusano, 1991). On
the other hand, the age of the infection (the pre-treatment interval) and the density of
the infecting organisms have hardly been investigated, although their impact on overall
success of an antimicrobial treatment can be assumed from clinical observation in such
diseases as Gram-negative septicaemia in the granulocytopenic host (Hughes et al.,
1990).
In the present experimental work the impact on the efficacy of three well-known
antipseudomonal agents (gentamicin, ticarcillin and ceftazidime) against Pseudomonas
aeruginosa of the pre-treatment interval and the number of bacteria at the site of
infection were investigated. The experimental model was an artificial infection in the
thighs of normal and granulocytopenic mice. After infection with a standardized
inoculum, treatment in different groups of infected mice was started immediately or
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after a delay of 2, 4, 6 or 8 h. Dosage regimens of study drugs were chosen to give
pharmacokinetic profiles similar to those seen in humans, where appropriate (Gerber et
al., 1986; Gerber, 1991). Therapeutic efficacy was assessed by quantification of the
number of bacteria at the site of infection over time and compared with plasma drug
concentrations.
Materials and methods
Bacterial strain
All the main experiments were performed with P. aeruginosa A10, which was a clinical
isolate obtained from Institute of Hygiene and Medical Microbiology, Bern,
Switzerland.
Media
Trypticase Soy Agar TSA (BBL, Division of Becton, Dickinson & Co., MD, USA) was
used for the determinations of cfu. Plasma drug concentrations were determined on
Diagnostic Sensitivity Test Agar (DST, Oxoid Ltd, Basingstoke, Hampshire, UK).
Drugs
All drugs were commercial products: gentamicin (Schering Corp., Kennilworth, NY);
ticarcillin (Beecham AG, Bern, Switzerland); ceftazidime (Glaxo Group, Greenford,
UK); cyclophosphamide (ASTA Werke AG, Bielefeld, Germany). The drugs were
dissolved in distilled water according to the recommendations of the manufacturers.
Further dilutions were made in physiological, pyrogen-free saline.
Animals
Female ICR-mice with a mean body weight of 28 g (27-31 g) were obtained from
Tierzuchtinstitut des Universitatsspitals der Universitat Zurich, Switzerland.
Production ofleucopenia
After an adaptation period of two days the mice were injected intraperitoneally with a
first dose of cyclophosphamide (Endoxan), 150 mg/kg in 1 mL sterile saline. Two days
later a second injection of 100 mg/kg in 1 mL saline was given. This treatment resulted
in a severe leucopenia which lasted for at least four days (Gerber et al., 1982).
Determination of plasma drug concentrations
Plasma kinetics were determined in the same groups of mice that were used to study
the drug's efficacy. Blood was drawn from the retro-orbital sinus of ether-anaesthetized
mice into heparinized microcapillaries (Clay Adams, Dickinson & Co). Plasma drug
concentrations were determined the same day by a biological method (Sabath &
Anhalt, 1980). Bacillus subtHis ATCC 6633 was used as the indicator bacterium for
determinations of gentamicin and ticarcillin concentrations, and Escherichia coli
ATCC 25922 for ceftazidime.
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Bacterial inocula and bacterial challenge
Starting from several colonies of a pure culture of P. aeruginosa A10 a broth culture
(Mueller-Hinton broth, supplemented with calcium and magnesium, as described by
Stratton & Reller, 1977) was inoculated and serially diluted. After overnight incubation
at 37°C the culture was chosen that came closest to an optical density of 0.3 (read at
580 nm), which corresponded to approximately 10* cfu/mL. The culture was centri-
fuged (2000 g for 10 min), washed in physiological saline and resuspended to result in
108 cfu/mL. An inoculum of 0-1 mL was injected into one thigh of ether-anaesthetized
mice. In each individual experiment the challenge inoculum was quantitated by cfu
determinations.
Quantification of cfu in the thigh of infected animals
At various time intervals after bacterial challenge and after onset of treatment three to
four mice were killed. The infected thigh was dissected and homogenized on ice in a
Polytron tissue homogenizer (Kincmatica, Luzern, Switzerland) in 4 mL ice-cold saline
supplemented with 8-5 g/L NaCl, 50 mg/L Ca++, 20 mg/L Mg++ and 1 mL /Macta-
mase (Watman Biochemicals, Maidstone, Kent, UK). Aliquots of serially diluted
mouse-thigh homogenates were plated on agar plates and cfu counts were determined
after incubation for 18-24 h.
Antimicrobial chemotherapy and determinations of plasma pharmacokinetics
All drug injections were made in aliquots of 0-1 mL subcutaneously. Treatment was
started immediately after bacterial challenge (0 h) or 1, 2, 4, 6, 8 or 10 h later.
Gentamicin was given as a single, human-equivalent dose of 32 mg/kg (see Discussion
for the definition of 'human-equivalent'). Ticarcillin and ceftazidime were given in
fractionated decreasing doses such that a human-like pharmacokinetic profile could be
obtained (Gerber et al., 1986, 1991; Gerber, 1991). Thus, the total dose of ticarcillin
(1000 mg/kg) was given over 6 h in fractionated doses, every 15 min, as follows: 225,
120, 3 x 80, 3 x 52, 3 x 34, 3 x 22, 3 x 14, 3 x 9, 3 x 6 and 4 mg/kg. The total dose of
ceftazidime (250 mg/kg) was injected in decreasing fractional doses every 20 min for a
total of 8 h as follows: 56, 25, 30, 3 x 20, 3 x 13, 3 x 8-5, 3 x 5, 3 x 3-5, 3 x 2-25, 3 x 1-5
and 1 mg/kg. Untreated control mice were injected with equal total amounts of sterile
saline.
Results
Antimicrobial susceptibility of P. aeruginosa .470
In standardized diffusion tests P. aeruginosa A10 was susceptible to the three study
drugs gentamicin, ticarcillin and ceftazidime. MICs (and MBCs) were 8 (16) mg/L of
gentamicin, 16 ( > 256) mg/L of ticarcillin and 1 (8) mg/L of ceftazidime.
Growth of P. aeruginosa AW in normal and granulocytopenic mice
In comparative growth curves in normal and granulocytopenic mice, the clinical isolate
of P. aeruginosa (A 10) proved to be more virulent than the conventionally used
laboratory strain ATCC 27853. The generation time of this bacterium in granulocyto-
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Figure 1. Bactericidal effect of a single dose of gentamicin (32 mg/kg) on P. aeruginosa A10 in normal mice
after various pre-treatment intervals. • , Geometric mean of cfu/thigh± 1 SD in four mice as obtained 2 h
after the gentamicin injection; O, control saline injections; • , mean gentamicin plasma concentration (± 1 SD)
2 h after the gentamicin injection. The impact of the pre-treatment interval on bactericidal efficacy was highly
significant and so was the gentamicin accumulation in mice after a pre-treatment interval of > 10 h.
penic mice (0-98 h) was significantly shorter than that in normal, non-granulocytopenic
mice (1-86 h).
Pharmacokinetics of the study drugs in plasma
In previous experiments the plasma half-life of gentamicin in mice was found to be
20 min (Gerber et al., 1986). In the experiments described below, this proved to be
similar in freshly infected gentamicin-treated mice but not in septicaemic mice. For
ticarcillin and ceftazidime a human-like pharmacokinetic profile was simulated, since in
previous experiments these drugs had been shown to be poorly effective when given as a
single bolus injection (Gcrber, 1991; Gerber et al., 1991). By fractionation of the total
dose of ticarcillin (1000 mg/kg given over 6 h), plasma peak concentrations of
185 ± 28 mg/L and a plasma half-life of 88 min were obtained. This kinetic profile
resulted in supra-MIC concentrations of ticarcillin for P. aeruginosa A10 for 6 h. The
human-adapted pharmacokinetic profile of ceftazidime showed a plasma peak concen-
tration of 108 ± 17 mg/L (after 20 min) followed by a half-life of 131 min. Supra-MIC
concentrations of ceftazidime for P. aeruginosa A10 persisted for a total of 8 h. Thus,
plasma peak concentrations and half-lives of the two /Mactam antibiotics corresponded
to values usually seen in healthy human volunteers.
Efficacy of gentamicin impact of the pre-treatment interval
The impact of the pre-treatment interval on the efficacy of gentamicin is shown in
Figures 1 and 2 for normal and granulocytopenic mice, respectively. In the thigh of
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Figure 2. Impact of the pre-treatment interval on the antimicrobial efficacy of a single dote of gentamicin
(32 mg/kg) on P. aentginosa A10 in granulocytopenic mice. See Figure 1 for the key to the symbols.
untreated control mice pseudomonas grew log-linearly. In contrast, in normal mice, an
initial inoculum of 106 organisms replicated very unreliably (not shown), and for this
reason experiments using non-granulocytopenic mice were started with an inoculum of
107 cfu per thigh. Thigh swelling occurred in normal and granulocytopenic mice
approximately 3 to 4 h after bacterial challenge. Untreated, non-granulocytopenic
control mice died within 14-24 h after bacterial challenge. In contrast, untreated
granulocytopenic animals clearly had an overwhelming infection resulting in early
septicaemia, shock and death within 14 to 16 h.
When gentamicin treatment was started at the time of bacterial challenge, a
pronounced bactericidal effect was obtained in normal and in granulocytopenic
animals. More than 99% of the bacteria died within 2 h. However, increasing the pre-
treatment interval resulted in a substantial reduction in bacterial killing. A pre-
treatment interval of more than 4 h in normal mice and more than 6 h in granulocyto-
penic mice almost completely abrogated the bactericidal effect. This abrogation of
antimicrobial efficacy was most impressive when it was correlated with the plasma drug
concentrations. In fact, probably owing to shock, the drug almost failed to be
eliminated in the very ill animals. As a consequence of abolished drug elimination,
plasma gentamicin concentrations of more than 20 mg/L persisted in animals with
treatment onset later than 8 h after bacterial challenge. Paradoxically, such supra-MBC
concentrations of gentamicin had a very poor antipseudomonal effect.
Efficacy of ticarcillin: impact of the pre-treatment interval
Experiments with ticarcillin were similar to those performed with gentamicin with the
one exception that the drug was given in such a manner that a human-like pharmaco-
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2 h after treatment onset 6 h after treatment onset
Figure 3. Impact of the pre-treatment interval on antipseudomonal efficacy of a human-simulated single
dose of ticarcillin in normal (a) and granulocytopenic (b) mice. Q, Surviving bacteria (% of the pre-treatment
cfu value per thigh (±1 SD)). Circled numbers within the ban represent the pre-treatment interval (h). The
left panels represent the numbers surviving after 2 h of treatment; the right panels those surviving after 6 h of
treatment • , Ticarcillin plasma concentrations determined at 2 h (left panels) and 6 h (right panels). See
text for comment.
kinetic profile was simulated. A bactericidal effect was observed after 2 or 6 h of
treatment provided that ticarcillin had been started earlier than 2 to 4 h after bacterial
challenge (Figure 3). In contrast, a merely bacteriostatic effect was obtained whenever
the onset of ticarcillin treatment was further delayed. In both normal and granulocyto-
penic mice, the maximal antibacterial effect of ticarcillin treatment was obtained after
2 h despite the fact that supra-MIC ticarcillin plasma concentrations were maintained
for four additional hours. Thus, a long pre-treatment interval clearly abrogated any
bactericidal effect of ticarcillin.
Drug accumulation also proved to be dependent on the duration of the pre-treatment
interval (Figure 3). Drug accumulation in granulocytopenic mice was significantly
greater than in normal mice. As in gentamicin-treated mice, this phenomenon was
probably due to persistent shock in granulocytopenic mice. However, despite the
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Figure 4. Impact of pre-treatment interval on the antibacterial efficacy of ceftazidime in normal (a) and
granulocytopenic (b) mice. Effect (D) and drug concentration ( • ) as obtained with human-adapted dosing.
Left and right panels show the results obtained 2 and 8 h after treatment onset, respectively. Circled numbers
represent the pre-treatment interval (tge of the infection) which had a significant impact on the efficacy of
ceftazidime.
persisting supra-MIC drug levels in granulocytopenic (as opposed to normal) mice,
antimicrobial efficacy was still poor. This was most evident in granulocytopenic
animals with a pre-treatment interval of 8 h. These animals all died despite a highly
significant accumulation of ticarcillin (Figure 3(b)).
Antibacterial efficacy of ceftazidime: impact of the pre-treatment interval
Ceftazidime was the second /Mactam drug studied. Like ticarcillin, it was administered
in fractionated doses such that a human-like pharmacokinctic profile was obtained. A
total dose of 250 mg/kg of ceftazidime proved to be significantly bactericidal in normal
as well as in granulocytopenic mice (Figure 4). Again, however, a highly significant
correlation between the duration of pre-treatment interval and antimicrobial efficacy
was found. If antimicrobial therapy with ceftazidime had not been started by 4 to 6 h
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after bacterial challenge, a merely bacteriostatic effect was seen during the 8 h treat-
ment. When the onset of treatment in leucopenic mice was delayed for 8 h after
bacterial challenge (i.e. when the bacteria had grown to 10s cfu/mL) no cidal effect
whatsoever could be obtained despite the fact that the drug accumulated in these mice
up to 60 mg/L (i.e. to 60 times and eight times the MIC and MBC, respectively).
Discussion
Our investigations have clearly demonstrated the impact on antimicrobial efficacy of a
period between bacterial challenge and onset of treatment with gentamicin, ticarcillin
or ceftazidime. The impact of the pre-treatment interval (IPTI) correlated with the
duration of this interval. The results of our study are in accord with the clinical truism
that successful antimicrobial therapy varies with the severity of the bacterial infection.
This clinical experience is most evident in granulocytopenic patients (Love, Schimpff &
Schiffer, 1980; Hughes et al., 1990).
Our studies were performed with a single treatment course of 6 to 8 h duration; drug
doses were used which may look very high. It must be emphasized however, that (with
the exception of gentamicin) drug levels in the plasma of the study animals reflected
those normally seen under clinical conditions. By using the method of fractionating
dosing we could approximate human pharmacplcinetic profiles of the two /Mactam
drugs. We have previously shown that the therapeutic effect of /Mactam antibiotics
depends not only on the total amount of injected drug, but equally on the 'shape' of the
area under the plasma concentration versus time-curve (Gerber et al., 1986, 1991;
Gerber, 1991). In those experiments we had found in mice the human-equivalent dose
and defined it as the amount of drug that was needed to simulate the human
pharmacokinetic profile.
In the present study we did not simulate the human pharmacokinetic profile of
gentamicin since earlier studies had shown that a single does of 32 mg/kg injected into
mice corresponded to the human-equivalent dose, as this amount of drug was needed to
simulate in a mouse the human pharmacokinetic profile. The shape of the AUC of
gentamicin was not relevant to the efficacy of this particular drug (Gerber et al., 1986).
Our present study demonstrates that a pre-treatment interval can completely abolish
the bactericidal effect of potentially bactericidal antibiotics. Moreover, if a very long
pre-treatment interval was chosen, the animals became so severely ill that the study
drug was not eliminated and hence accumulated to potentially toxic concentrations.
Nevertheless, these extremely high drug concentrations proved to be less bactericidal
than the very much lower drug concentrations seen after early treatment onset. Thus,
for overall therapeutic efficacy the severity of the infection seems to be more important
than the heights of attainable plasma levels or the overall AUC of the therapeutic
agent.
Against Gram-positive cocci the impact on antimicrobial efficacy of both inoculum
size and age of infection on experimental therapeutic efficacy has been known since the
early days of penicillin (Eagle, 1949; Smith & Wood, 1956). Pneumococci were easily
eradicated with small doses of penicillin provided that penicillin treatment was started
at the first day of infection and suppuration was absent (Smith & Wood, 1956). The
phenomenon was explained by the poor growth rate of the target bacteria in pus, but
equally by the poor phagocytic activity of leucocytes in pus. More recently this
phenomenon has been termed phenotypic tolerance and its mechanism has been partly
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elucidated (Tuomanen, 1986). Phenotypic tolerance in non-growing pneumococci was
shown to correlate with the loss of autolysin molecules followed by a progressive
change in the cell wall structure, which becomes less susceptible to autolysin-induced
hydrolysis (Tuomanen & Tomasz, 1991).
Against Gram-negative bacteria and P. aeruginosa in particular abrogation of anti-
microbial activity by postponed treatment onset has previously been observed. As early
as in 1956, Miles reported that streptomycin exerted a protective effect against
P. aeruginosa infection only when treatment was started within 3 h. He termed this 3-h
interval the decisive period. More recently, Davey, Barza & Stuart (1987, 1988),
reported on antipseudomonal chemotherapy in experimental endophthalmitis and in
the rat croton oil pouch model. Treatment with ciprofloxacin, gentamicin and
imipenem was effective when started after 24 h of infection, but had little or no effect
when delayed until 48 h after infection. Similarly, the pre-therapeutic duration of
infection reduced the efficacy of ceftazidimc and ciprofloxacin in Klebsiella pneumoniae
pneumonia and septicaemia in leukopenic rats (Roosendaal et al., 1991).
Various factors might explain the effect of the pre-treatment interval on efficacy
against Gram-negative bacteria. In previous studies (Davey et al., 1987, 1988) the
relative bacterial resistance after delayed treatment onset was attributed to slower
growth of the target organisms. This could definitely not be the decisive factor in our
model, since treatment efficacy was diminished before the target bacteria came into a
lag-phase. Thus, other factors must be involved. It is well known from in-vitro studies
that a high density of /Mactamase producing bacteria diminishes the effect of /Mactam
antibiotics (inoculum effect). The concentration of bacterial /Mactamases probably
correlates with the density of the bacterial inoculum (Sabath et al., 1975; Eng, Smith &
Cherubin, 1984; Hall & Opfer, 1984).
Another explanation of the inoculum effect could be that at very high bacterial
densities bacterial clusters are formed through which the drug may hardly penetrate, so
that the inner bacteria are protected. This mechanism of an inoculum effect may be of
particular importance for /Mactam drugs such as ticarcillin and ceftazidime which
predominantly bind to penicillin-binding protein 3 resulting in formation of bacterial
filaments. Filaments are likely to be formed at the surface of bacterial clusters, and
these may further hamper the penetration of the drug into the clusters (Gwynn, Webb
& Rolinson, 1981). Preliminary histological observations in our mouse thigh model
revealed indeed very dense accumulations of bacteria and the formation of bacterial
filaments in /Mactam treated animals.
Other mechanisms are likely to interfere with the activity of aminoglycosides. The
biochemical environment at the site of infection could explain, at least in part, the effect
of pre-treatment delay on the effectiveness of gentamicin in particular. The anti-
microbial activity of aminoglycosides is greatly affected by a low pH and a low redox
potential, i.e. factors known to be low at the site of infection (Hays & Mandell, 1974;
Verklin & Mandell, 1977). Yet another mechanism could be some bacterial adap-
tation to the environment in vivo which in turn might lead to reduced susceptibility of
the target organisms to various antimicrobial agents.
Finally, many different organisms and P. aeruginosa in particular produce an
extracellular matrix which might well have a protective effect (Nickel et al., 1985). The
production of this matrix is reversible and is hence probably due to genetic regulatory
events or phenotypical changes (Bryan, 1989).
Our present work contributes to our understandings of the phenomenon of the pre-
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treatment interval—a factor of paramount importance for the study of antimicrobial
activity in vivo.
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